Fly News Breaks for August 19, 2019
Aug 19, 2019 | 11:16 EDT
Piper Jaffray analyst Matt O'Brien said he views the results of ViewRay's prostate cancer study as "a highly compelling example of the unique advantages of the MRIdian system" and thinks these results, along with further MRIdian data, should continue to make the selling process for the company easier. The analyst, who expects ViewRay to take market share in upcoming quarters, keeps an Overweight rating on the stock.
News For VRAY From the Last 2 Days
Nov 18, 2019 | 09:33 EST
Conference call with CEO Drake and COO Matin will be held on November 18 at 1 pm hosted by Cantor Fitzgerald.